

## REPORT ON DEINOVE'S LIQUIDITY CONTRACT WITH BIL FINANCE - JUNE 30, 2013

**Paris July 6, 2013**

DEINOVE (Alternext Paris: ALDEI), a technological company that designs, develops and markets a new generation of industrial processes based on Deinococci bacteria, reports today about the liquidity contract entrusted by DEINOVE to BIL FINANCE. As at June 30, 2013, the following assets appeared on the liquidity account:

- Number of shares: 4,083 shares of DEINOVE
- Cash position: € 136,580.10

For information, the following assets appeared on the liquidity account at the previous report as at December 31, 2012:

- Number of shares: 4,119 shares of DEINOVE
- Cash position: € 127,156.97

### ABOUT DEINOVE

DEINOVE (Alternext Paris: Aldei) is a biotechnology company that designs and develops new production systems based on bacteria with untapped potential: the *Deinococcus*. Taking advantage of the unique genetic properties and unusual robustness of *Deinococcus*, the synthetic biology experts at DEINOVE optimize the enzymatic and metabolic capabilities of these natural "micro-factories" to manufacture rare compounds or products that are not achievable using classic chemical and enzymatic processes: second generation bioethanol (DEINOL); enzymes for bioremediation of plastics (THANAPLAST™); new antibiotics (DEINOBIOTICS); terpenoids for chemistry, cosmetics and biopharmaceuticals (DEINOCHEM).

DEINOVE is currently focusing on making the DEINOL program for cellulosic bioethanol production a success. This program is granted with €8.9m by OSEO and is backed up by the sugar group TEREOS, the French leader and the second European producer of bioethanol. DEINOL recently achieved a worldwide breakthrough when a *Deinococcus*, selected and optimized by DEINOVE, has successfully turned wheat-based biomass into ethanol, in a single operation and without additives. In 2014, at the end of the laboratory pilot phase, TEREOS will be responsible for validating the full-scale process at its factory in Lillebonne (France), within the framework of a first non-exclusive license.

Listed on Alternext since April 2010, DEINOVE was founded by Dr Philippe POULETTY, General Partner of Truffle Capital, and Pr Miroslav RADMAN, Professor at the Faculty of Medicine of the Université René Descartes. With a workforce of about 30 people, it conducts R&D programmes in partnership with the CNRS (Marseille and Montpellier), INSA (Toulouse) and the VTT (Finland). The Company is headquartered in Paris, with laboratories located in the Cap Alpha Technology Park in Montpellier (France).

*More information at [www.deinove.com](http://www.deinove.com)*

### CONTACTS

#### DEINOVE

**Julen COSTE**

Director of Finance & Administration

Tel: +33 (0) 1 42 03 27 37

[julien.coste@deinove.com](mailto:julien.coste@deinove.com)

#### ATCG Press

**Marielle BRICMAN**

Mob: +33 (0) 6 26 94 18 53

[deinove@atcg-partners.com](mailto:deinove@atcg-partners.com)

**Elisabetta CASTELLI**

Director of Communications

Tel: +33 (0) 1 42 03 27 37

[elisabetta.castelli@deinove.com](mailto:elisabetta.castelli@deinove.com)

**ALDEI**  
**LISTED**  
**NYSE**  
**ALTERNEXT**